CYT387 sulfate salt

• CAT Number: I000294
• CAS Number: 1056636-06-6
• Molecular Formula: C23H26N6O10S2
• Molecular Weight: 610.62
• Purity: ≥95%
• Target: JAK
• Solubility: DMSO: ≥ 6.1 mg/mL
• Storage: Store at -20°C
• IC50: 11 nM/18 nM(JAK1/JAK2) [1]
• IUPAC Name: N-(cyanomethyl)-4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]benzamide;sulfuric acid
• InChI: InChI=1S/C23H22N6O2.2H2O4S/c24-10-12-25-22(30)18-3-1-17(2-4-18)21-9-11-26-23(28-21)27-19-5-7-20(8-6-19)29-13-15-31-16-14-29;2*1-5(2,3)4/h1-9,11H,12-16H2,(H,25,30)(H,26,27,28);2*(H2,1,2,3,4)
• InChIKey: XJGPMRGWDSQVTN-UHFFFAOYSA-N
• SMILES: C1COCCN1C2=CC=C(C=C2)NC3=NC=CC(=N3)C4=CC=C(C=C4)C(=O)NCC#N.OS(=O)(=O)O.OS(=O)(=O)O

CYT387 sulfate salt (Cat.No:I000294) is a salt form of CYT387, a potent inhibitor of Janus kinase 1 and 2 (JAK1/2). It has demonstrated promising anti-inflammatory and immunomodulatory effects, making it a potential therapeutic option for inflammatory and autoimmune diseases. Further research is ongoing to assess its efficacy and safety profiles. 

Reference

[1]. Pardanani A, et al. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia, 2009, 23(8), 1441-1445.
[2]. Monaghan KA, et al. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells. Leukemia, 2011, 25(12), 1891-1899.
[3]. Tyner JW, et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood, 2010, 115(25), 5232-5240.